'Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice. A protein identified nearly 40 years ago ...
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...
A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.
3D rendering of the tumor microenvironment. The recipe for a general and long-lasting cancer treatment could involve regulatory T cells, a type of white blood cell. This is the first installment in a ...
Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.
A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, critical role in dampening the immune system’s response to cancer. Blocking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results